Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)8.69
  • Today's Change-0.09 / -1.03%
  • Shares traded401.36k
  • 1 Year change-13.96%
  • Beta0.4233
Data delayed at least 15 minutes, as of Jul 14 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter (OTC) products and ophthalmic surgical devices and instruments. The Salix segment consists of sales in the U.S. of gastroenterology products. The International segment consists of sales, except for sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Diversified segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Bausch + Lomb segment includes Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.

  • Revenue in CAD (TTM)13.32bn
  • Net income in CAD-54.75m
  • Incorporated2013
  • Employees20.70k
  • Location
    Bausch Health Companies Inc2150 St. Elzear Blvd. WestLAVAL H7L 4A8CanadaCAN
  • Phone+1 (514) 744-6792
  • Fax+1 (514) 744-6792
  • Websitehttps://www.bauschhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Twist Bioscience Corp475.99m-261.69m3.12bn923.00--5.17--6.55-3.26-3.265.907.350.53557.238.09376,684.70-29.44-28.50-33.07-31.5646.7039.40-54.98-93.824.24--0.00--27.6941.91-2.01---19.22--
Vimian Group AB624.46m30.83m3.13bn1.20k101.772.8635.635.010.41230.41238.3714.690.3751.766.483,633,974.001.96--2.20--69.01--5.23--1.224.870.2423--12.95--88.01------
Ligand Pharmaceuticals Inc248.47m-181.57m3.21bn68.00--2.95--12.94-7.12-7.129.7341.270.19950.72555.422,668,941.00-14.581.82-15.221.9292.8182.57-73.0710.305.02-0.28330.000030.0027.286.80-107.49---6.53--
Bausch Health Companies Inc13.32bn-54.75m3.24bn20.70k----2.020.2436-0.1486-0.148636.07-4.380.36491.754.72643,468.30-0.3038-1.66-0.3786-2.0670.7871.26-0.8324-5.560.96781.361.01--9.912.2892.23--4.11--
Apellis Pharmaceuticals Inc1.06bn-306.23m3.34bn705.00--14.88--3.15-1.79-1.796.231.310.94661.083.081,100,482.00-27.29-61.31-35.92-76.5383.0086.49-28.83-157.263.62-5.430.7341--97.02--62.57---24.96--
Nanjing King-Frind Bchmcl Phrmctcl C Ltd726.59m140.12m3.38bn1.36k24.112.69--4.650.45460.45462.354.070.40990.60494.162,797,451.007.908.3810.3512.0341.7844.9519.2819.722.0956.950.185823.22-0.19849.70536.096.4334.44-6.04
Liaoning Cheng Da Co Ltd2.18bn89.57m3.41bn3.32k37.170.6027--1.560.31370.31377.4519.350.23735.006.413,436,062.002.053.152.944.5512.7713.958.649.880.863--0.275916.444.70-8.65-10.09-29.33-9.31-27.52
Data as of Jul 14 2025. Currency figures normalised to Bausch Health Companies Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.